Precision Palliative Care as a Pragmatic Solution for a Care Delivery Problem This study evaluated tarlatamab in patients with relapsed/refractory SCLC. The primary end point was safety. Secondary end ...

-- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached -- -- Preliminary results from 58 patients ...

Encouraging anti-tumour activity seen across all dose levels and in various tumour indications Clinical benefit rate of 80% for 10 patients with HER2+ oesophageal cancer who had received prior therapy ...

SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment ...

Elite colleges have long been filled with the children of the richest families: At Ivy League schools, one in six students has parents in the top 1 percent. A large new study, released Monday, shows ...

Smaller class sizes in schools are failing to increase the resilience of children from low-income families, according to a new study. Smaller class sizes in schools are failing to increase the ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...